Propionyl-CoA carboxylase alpha chain (PCCA)

Propionyl-CoA carboxylase alpha chain (PCCA) is one subunit of the heterododecameric mitochondrial enzyme complex known as propionyl-CoA carboxylase (PCC). This biotin-dependent enzyme catalyzes the ATP-dependent conversion of propionyl-CoA into D-methylmalonyl-CoA, a key step in breaking down odd-chain fatty acids and certain amino acids. The complex consists primarily of two types of subunits—alpha and beta—with the alpha chain containing both biotin-binding domains essential for catalysis and interaction domains necessary for holoenzyme assembly. Deficiency or dysfunction due to mutations in either PCCA or its partner beta subunit leads to accumulation of toxic metabolites resulting in propionic acidemia, a severe inherited metabolic disorder characterized by life-threatening acidosis especially during infancy. Therapeutic strategies under investigation include gene therapy and small molecules that restore enzymatic activity by targeting either expression levels or catalytic efficiency. Structurally, each PCC holoenzyme contains six active sites formed at interfaces between different subunits; substrate binding induces conformational changes critical for catalysis. The enzyme plays an essential role not only in energy metabolism but also serves anaplerotic functions by replenishing intermediates into gluconeogenesis via succinylcholine formation from methylmalonylcholine through subsequent steps involving other enzymes such as methylmalonylcholine mutase—a process dependent on vitamin B12 availability[1][4][7].

Other names

PCCAPropionyl CoA Carboxylase Subunit AlphaPropionyl-CoA carboxylase alpha subunitMitochondrial propionyl-CoA carboxylase alpha chain

Enzyme replacement or activation therapy to restore deficient PCC activity in patients with genetic mutations causing loss-of-function. Gene therapy approaches aim to deliver functional copies of the PCCA gene to patient cells. Small molecule activators may enhance residual enzymatic activity where partial function remains due to hypomorphic mutations.